OHSU scientists test medication to treat involuntary weight loss
Scientists at Oregon Health & Science University, in collaboration with Neurocrine Biosciences Inc., have successfully tested a research medication that both stimulates appetite and reduces metabolic rate in preclinical trials. Neurocrine, which developed the test medication for this research, is now developing a related medication that will likely be tested in patients suffering from a common, disease-related form of malnutrition and involuntary weight loss called cachexia. The results of the research are published in the current online edition of the journal Endocrinology.
"Weve all seen AIDS and cancer patients who lose their appetites and suffer from involuntary weight loss. They lose muscle mass and become very frail as their disease progresses -- this is what we refer to as cachexia," explains Daniel Marks, M.D., Ph.D., a member of the OHSU Center for Weight Regulation and Associated Disorders and an assistant professor of pediatric endocrinology in the OHSU School of Medicine. "Cachexia is a very serious and currently untreatable disorder that can often impede the battle against the related disease. For instance, cancer patients who are malnourished due to cachexia cannot undergo intense chemotherapy simply because their bodies are too frail to handle it. If we can prevent cachexia and keep these patients from deteriorating physically, it gives them a greater chance of surviving the disease they are fighting."
This latest research breakthrough is based on earlier studies that demonstrated how a receptor on certain brain cells -- called the MC4 receptor -- can influence metabolism and appetite. Previous research involving mice demonstrated that when this specific cell receptor is blocked by delivering medications directly to the brain, the effects of cachexia are reversed. The animals appetite and weight increase while their metabolic rate decreases. The next step in the research process, and the goal of this study, was to develop and test a medication that would have the same effect. This medication, and others in its class, have excellent oral absorption, which also enhances their appeal as drug candidates.
In this research, the scientists gave both normal mice and mice with a cachexia-like syndrome Neurocrines orally-administered medication that blocks the MC4 receptor in the brain. In both cases, the animals appetites increased and their metabolic rates decreased, ultimately resulting in the resumption of normal growth and accumulation of muscle mass. Researchers now hope to conduct clinical trials where both healthy human patients and those suffering from cachexia receive related oral medications to determine the drugs safety and effectiveness.
"We believe the results obtained in this collaborative study with OHSU will provide an important proof-of-principle for Neurocrines small molecule MC4 receptor antagonist program in animal models relevant for cachexia," said Alan C Foster, Ph.D., Neurocrine Fellow and head of Neurocrines neuroscience group. Neurocrine is a San Diego-based company that is developing medications related to weight regulation. "We hope to advance an optimized molecule into the first stages of human clinical testing later this year."
"While a lot of attention is paid to the countrys obesity epidemic, researchers at OHSU also investigate the other side of weight regulation which is not as well-publicized -- extreme weight loss," said Roger Cone, Ph.D., director of the Center for the Study of Weight Regulation and Associated Disorders. "Cachexia and disorders like it can have extremely serious consequences on patients. This research not only provides hope for these patients, it is also provides another important piece of the puzzle in regards to the brains control over weight regulation."
The Center for the Study of Weight Regulation and Associated Disorders is a new research institute at Oregon Health & Science University in which scientists and physicians work together to address the important basic and clinical questions surrounding weight regulation. Researchers at OHSU have been involved in a number of key weight regulation discoveries, including identification of specific cells in the brain that are crucial to weight control, and the possible connection between infant hormone exposure and lifelong weight issues. Another key role of the center is to provide a base of expertise for public (community) education, and serve as a source for continuing education in the treatment of weight-related disorders, such as obesity, diabetes, anorexia and cachexia.
Jim Newman | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...